[1] NIU D M, CHIEN Y H, CHIANG C C, et al. Nationwide survey of extended newborn screening by tandem mass spectrometry in Taiwan[J]. J Inherit Metab Dis,2010,33(Suppl 2):S295-S305.
[2] 杨楠,韩连书,叶军,等.新生儿期氨基酸、有机酸及脂肪酸氧化代谢病疾病谱分析[J].临床儿科杂志,2012,30(9):805-808. YANG Nan, HAN Lianshu, YE Jun, et al. Diseases spectrum of metabolism disease of amino acid, organic acid and fatty acid oxidation in neonates[J]. Journal of Clinical Pediatrics,2012,30(9):805-808. (in Chinese)
[3] 赵正言.新生儿遗传代谢病筛查进展[J].中国实用儿科杂志,2014,29(8):587-589. ZHAO Zhengyan. Advances in neonatal genetic metabolic diseases screening[J]. Chinese Journal of Pediatrics,2014,29(8):587-589. (in Chinese)
[4] KASPER D C, RATSCHMANN R, METZ T F, et al. The national Austrian newborn screening program-eight years experience with mass spectrometry. past, present, and future goals[J]. Wien Klin Wochenschr,2010,122(21-22):607-613.
[5] VILARINHO L, ROCHA H, SOUSA C, et al. Four years of expanded newborn screening in Portugal with tandem mass spectrometry[J]. J Inherit Metab Dis,2010,33 Suppl 3:S133-S138.
[6] ZYTKOVICZ T H, FITZGERALD E F, MARSDEN D, et al. Tandem mass spectrometric analysis for amino, organic, and fatty acid disorders in newborn dried blood spots:a two-year summary from the New England Newborn Screening Program[J]. Clin Chem,2001,47(11):1945-1955.
[7] NIU D M, CHIEN Y H, CHIANG C C, et al. Nationwide survey of extended newborn screening by tandem mass spectrometry in Taiwan[J]. J Inherit Metab Dis,2010,33(Suppl 2):S295-S305.
[8] FRAZIER D M, MILLINGTON D S, MCCANDLESS S E, et al. The tandem mass spectrometry newborn screening experience in North Carolina:1997-2005[J]. J Inherit Metab Dis,2006,29(1):76-85.
[9] HARDELID P, CORTINA-BORJA M, MUNRO A, et al. The birth prevalence of PKU in populations of European, South Asian and sub-Saharan African ancestry living in South East England[J]. Ann Hum Genet,2008,72(Pt 1):65-71.
[10] OZBEN T. Expanded newborn screening and confirmatory follow-up testing for inborn errors of metabolism detected by tandem mass spectrometry[J]. Clin Chem Lab Med,2013,51(1):157-176.
[11] DE BRAEKELEER M, LAROCHELLE J. Genetic epidemiology of hereditary tyrosinemia in Quebec and in Saguenay-Lac-St-Jean[J]. Am J Hum Genet,1990,47(2):302-307.
[12] RUSSO P A, MITCHELL G A, TANGUAY R M. Tyrosinemia:a review[J]. Pediatr Dev Pathol,2001,4(3):212-221.
[13] ALLARD P, GRENIER A, KORSON M S, et al. Newborn screening for hepatorenal tyrosinemia by tandem mass spectrometry:analysis of succinylacetone extracted from dried blood spots[J]. Clin Biochem,2004,37(11):1010-1015.
[14] HÄBERLE J, BODDAERT N, BURLINA A, et al. Suggested guidelines for the diagnosis and management of urea cycle disorders[J]. Orphanet J Rare Dis,2012,7:32.
[15] TUCHMAN M, LEE B, LICHTER-KONECKI U, et al. Cross-sectional multicenter study of patients with urea cycle disorders in the United States[J]. Mol Genet Metab,2008,94(4):397-402.
[16] CAVICCHI C, MALVAGIA S, LA M G, et al. Hypocitrullinemia in expanded newborn screening by LC-MS/MS is not a reliable marker for ornithine transcarbamylase deficiency[J]. J Pharm Biomed Anal,2009,49(5):1292-1295.
[17] JANZEN N, TERHARDT M, SANDER S, et al. Towards newborn screening for ornithine transcarbamylase deficiency:fast non-chromatographic orotic acid quantification from dried blood spots by tandem mass spectrometry[J]. Clin Chim Acta,2014,430:28-32.
[18] MEW N A, LANPHER B C, GROPMAN A, et al. Gene reviews[M]. Seattle:University of Washington,2003:1-15.
[19] LEE B H, KIM Y M, HEO S H, et al. High prevalence of neonatal presentation in Korean patients with citrullinemia type 1, and their shared mutations[J]. Mol Genet Metab,2013,108(1):18-24.
[20] MARCÃO A, FONSECA H, SOUSA C, et al. Two cases of late-onset argininosuccinic aciduria with normal results at newborn screening[J]. Ana Marcao spdm,2015,2(6):1-2.
[21] EDWARDS R L, MOSELEY K, WATANABE Y, et al. Long-term neurodevelopmental effects of early detection and treatment in a 6-year-old patient with argininaemia diagnosed by newborn screening[J]. J Inherit Metab Dis,2009,32 Suppl 1:S197-S200.
[22] JAIN-GHAI S, NAGAMANI S C, BLASER S, et al. Arginase Ⅰ deficiency:severe infantile presentation with hyperammonemia:more common than reported?[J]. Mol Genet Metab,2011,104(1-2):107-111.
[23] LU Y B, KOBAYASHI K, USHIKAI M, et al. Frequency and distribution in East Asia of 12 mutations identified in the SLC25A13 gene of Japanese patients with citrin deficiency[J]. J Hum Genet,2005,50(7):338-346.
[24] COUCE M L, BÓVEDA M D, GARCÍA-JIMÉMEZ C, et al. Clinical and metabolic findings in patients with methionine adenosyltransferase Ⅰ/Ⅲ deficiency detected by newborn screening[J]. Mol Genet Metab,2013,110(3):218-221.
[25] JANOSÍK M, SOKOLOVÁ J, JANOSÍKOVÁ B, et al. Birth prevalence of homocystinuria in Central Europe:frequency and pathogenicity of mutation c.1105C>T (p.R369C) in the cystathionine beta-synthase gene[J]. J Pediatr,2009,154(3):431-437.
[26] CHADWICK S, FITZGERALD K, WEISS B, et al. Thirteen patients with MAT1A mutations detected through newborn screening:13 years' experience[J]. JIMD Rep,2014,14:71-76.
[27] NELLIS M M, DANNER D J. Gene preference in maple syrup urine disease[J]. Am J Hum Genet,2001,68(1):232-237.
[28] MYERS K A, REEVES M, WEI X C, et al. Cerebral edema in maple syrup urine disease despite newborn screening diagnosis and early initiation of treatment[J]. JIMD Rep,2012,3:103-106.
[29] 李溪远,丁圆,刘玉鹏,等.枫糖尿症患儿13例临床、生化及基因研究[J].中国实用儿科临床杂志,2016,31(8):569-572. LI Xiyuan, DING Yuan, LIU Yupeng,et al. Clinical, biochemical and genetic features of 13 children with maple syrup urine disease[J]. Journal of Applied Clinical Pediatrics,2016,31(8):569-572. (in Chinese)
[30] COUCE M L, RAMOS F, BUENO M A, et al. Evolution of maple syrup urine disease in patients diagnosed by newborn screening versus late diagnosis[J]. Eur J Paediatr Neurol,2015,19(6):652-659.